J&J’s New Drug for Treatment-Resistant Depression
Why It Matters
Spado offers clinicians a fast‑acting option for TRD, potentially reducing suicide risk and redefining psychiatric care delivery, while creating new revenue streams for specialty clinics.
Key Takeaways
- •Spado nasal spray approved for treatment‑resistant depression in US.
- •Administration requires in‑clinic dosing and post‑treatment monitoring for patients.
- •Onset of effect occurs within five to ten minutes.
- •Only about one‑third of screened patients qualify for treatment.
- •Goal: aggressive, rapid remission akin to oncology care.
Summary
Johnson & Johnson’s newly FDA‑approved nasal spray, Spado (esketamine), targets patients with treatment‑resistant depression (TRD) and acute suicidal ideation. The drug, delivered via a nasal atomizer, represents the latest addition to the limited arsenal of rapid‑acting antidepressants.
Unlike traditional oral antidepressants, Spado must be administered in a certified clinic, where patients stay for several hours under continuous pulse‑oximetry, blood‑pressure, and mental‑status monitoring. Clinical trials showed symptom relief within five to ten minutes, but strict eligibility criteria limit enrollment to roughly one‑third of those screened.
Clinicians highlighted the experience: patients report feeling sleepy, detached, or “floating,” prompting careful observation. A physician recounted a 62‑year‑old on a 25‑year medication regimen, noting the lack of guidance on when to discontinue therapy and urging a cancer‑care model for psychiatry.
If adopted widely, Spado could reshape depression treatment by emphasizing rapid remission over weeks‑long titration, driving demand for specialized infusion centers and new reimbursement models. The shift may also pressure insurers and providers to integrate similar rapid‑acting agents into standard practice.
Comments
Want to join the conversation?
Loading comments...